AGS 499
Alternative Names: AGS-499Latest Information Update: 28 Sep 2023
At a glance
- Originator Ben Gurion University
- Developer Neuromagen Pharma
- Class Antidementias; Cardiovascular therapies; Neuroprotectants; Small molecules
- Mechanism of Action Telomerase activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Cardiovascular disorders
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Israel
- 27 Jun 2022 Preclinical trials in Alzheimer's disease in Israel (unspecified route), prior to June 2022 (Neuromagen Pharma pipeline, June 2022)
- 27 Jun 2022 Preclinical trials in Cardiovascular disorders in Israel (unspecified route), prior to June 2022 (Neuromagen Pharma pipeline, June 2022)